Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABS-1230 in healthy adults
NCT07156201Phase 1Recruiting
- Sponsor
- Actio Biosciences
- Start
- Aug 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ABS-1230 in KCNT1-related epilepsy (6 arms), sponsored by Actio Biosciences. Primary endpoints: Incidence, severity, and dose-relationship of adverse events at 4 weeks and Incidence, severity, and dose-relationship of clinically significant changes in laboratory parameters at 4 weeks. Started Aug 2025; status: recruiting.
02
Drugs
ABS-1230
03
Conditions
KCNT1-related epilepsy
Beyond the preview
Go deeper on NCT07156201.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07156201.